A patient with treatment-resistant depression sits in a clinic chair five days a week for four weeks. That's been the standard neuromodulation protocol for years — twenty sessions minimum, each requiring a commute, a waiting room, and a block of time most working people can't afford to lose. As of March 2026, the FDA just changed that equation.
Neurolief's Proliv™Rx has received Premarket Approval, making it the first wearable, at-home brain neuromodulation device cleared to treat Major Depressive Disorder in adults who haven't responded to at least one antidepressant. The technology, called external Combined Occipital and Trigeminal Afferent Stimulation (eCOT-AS), delivers targeted electrical pulses to neural pathways involved in mood regulation. No clinic visits required. No sedation. No systemic side effects.
BrainsWay, the Israeli neurotech company behind Deep TMS, invested $6 million in Neurolief on the strength of this approval, bringing their total stake to $11 million since August 2025. A third tranche of up to $5 million is tied to Neurolief hitting defined revenue targets, and BrainsWay holds a call option to acquire the company outright. This isn't a speculative play. It's a calculated move by the only TMS company with three FDA-cleared indications backed by pivotal clinical data.
What the MOOD Study Actually Showed
The evidence behind Proliv™Rx comes from the MOOD study, a multicenter, randomized, double-blind, sham-controlled trial published in Brain Stimulation. Patients self-administered the device at home over 16 weeks under physician supervision.
Remission rates hit 21.3% in the active group versus 6.0% for sham (P = .027). Patients receiving active treatment also showed statistically greater shifts from severe to mild depression categories on the Hamilton Depression Rating Scale (HDRS-17). During the open-label extension, where all participants received active treatment, the mean HDRS-17 score dropped by nearly 10 points from baseline (P < .0001) and remission rates climbed to 32%.
For context, many pharmaceutical antidepressants achieve remission rates between 25% and 35% in controlled trials. A wearable device used at home, without the metabolic disruption and sexual side effects common to SSRIs and SNRIs, producing comparable remission numbers deserves serious clinical attention. The safety profile was favorable throughout, with minimal adverse events and high patient adherence across the full study duration.
Why Neuromodulation Is Leaving the Clinic
The barrier to brain stimulation treatment has never been efficacy. BrainsWay's own Deep TMS holds three FDA clearances: MDD (including anxious depression), OCD, and smoking addiction. Their accelerated SWIFT protocol cut the traditional 20-visit treatment phase down to six half-day sessions. In January 2026, they secured the first payer coverage policy for that accelerated protocol, and in late 2025, they received clearance to treat adolescents aged 15 to 21 with MDD.
But even six clinic visits demand time, travel, and scheduling that filters out working patients. The executive running a company who can't block six mornings in a row. The parent of three who can't arrange that much childcare. The veteran in a rural county with no TMS clinic within 90 miles.
Proliv™Rx addresses the access problem without abandoning clinical rigor. It's physician-prescribed, clinician-supervised, and backed by Class III PMA data. The patient wears the device at home and follows a structured protocol. The physician still directs treatment; the patient simply doesn't have to be in the building for it to work.
The shift isn't away from physician oversight. It's past the outdated assumption that treatment only happens inside four clinic walls.
What This Means for Precision Brain Health
At The Neurogenesis Project, we use neuromodulation as one component within a broader diagnostic and therapeutic architecture. Our Intensive Brain Health Program starts by understanding each patient's brain state across multiple dimensions: metabolic function, vascular perfusion, structural integrity, inflammatory burden, and neurotransmitter balance. Only then do we build an intervention plan.
A device like Proliv™Rx fits naturally into that model. Consider the patient who completes an intensive in-clinic program targeting neuroinflammation, perfusion deficits, and neurotransmitter rebalancing, then returns home. Sustained neuromodulation between visits, combined with targeted brain-supportive supplementation, could reinforce the neuroplastic changes initiated during the intensive treatment window and extend clinical gains well beyond the clinic stay.
That's where the field is heading: precision diagnostics to identify the specific dysfunction, intensive intervention to shift the trajectory, and physician-directed home-based tools to maintain momentum. The brain doesn't stop needing support when a patient checks out. It's an ongoing process, a daily one, and the technology is finally catching up to what the neuroscience has demanded for years.
BrainsWay's $11 million investment in Neurolief tells us the neuromodulation industry sees the future in the patient's hands, literally. The brain is the most valuable asset you have, and maintaining it shouldn't require living next door to a specialty clinic. If you want to understand where your brain health stands today and what it needs to perform at its best, download our free brain health guide or request a consultation.